Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P D Ghislain

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Annales De Dermatologie Et De Venereologie|March 30, 1999
[Toxic dermatitis caused by tramadol]P D Ghislain, T Wiart, N Bouhassoun, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 28, 2021
Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY StudyA Hafner, P D Ghislain, R Kovács, et al.
The British Journal of Dermatology|October 15, 2013
Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1P Rich, M Bourcier, H Sofen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 1, 2020
Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1)J L W Lambert, S Segaert, P D Ghislain, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 22, 2019
A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis managementL Grine, M de la Brassinne, P-D Ghislain, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2020
Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)J L W Lambert, S Segaert, P D Ghislain, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 12, 2024
Belgian recommendations for managing psoriasis in a changing treatment landscapeR Speeckaert, A F Nikkels, J Lambert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2020
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasisJ F Merola, P-D Ghislain, J N Dauendorffer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2020
Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre studyF Benhadou, P D Ghislain, F Guiot, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 13, 2022
Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA studyM Augustin, P G Sator, R von Kiedrowski, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Annales De Dermatologie Et De Venereologie|March 30, 1999
[Toxic dermatitis caused by tramadol]P D Ghislain, T Wiart, N Bouhassoun, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 28, 2021
Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY StudyA Hafner, P D Ghislain, R Kovács, et al.
The British Journal of Dermatology|October 15, 2013
Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1P Rich, M Bourcier, H Sofen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 1, 2020
Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1)J L W Lambert, S Segaert, P D Ghislain, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 22, 2019
A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis managementL Grine, M de la Brassinne, P-D Ghislain, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2020
Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)J L W Lambert, S Segaert, P D Ghislain, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 12, 2024
Belgian recommendations for managing psoriasis in a changing treatment landscapeR Speeckaert, A F Nikkels, J Lambert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2020
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasisJ F Merola, P-D Ghislain, J N Dauendorffer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2020
Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre studyF Benhadou, P D Ghislain, F Guiot, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 13, 2022
Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA studyM Augustin, P G Sator, R von Kiedrowski, et al.
Pageof 4